Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guérin: 18-year experience

Objectives. Immunotherapy with bacille Calmette-Guérin (BCG) has been proposed in the past decade as first-line treatment for high-grade superficial bladder cancer (G3T1). We report our 18-year experience in the treatment of patients with G3T1 bladder cancer. Methods. From January 1989 to July 1997,...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Urology (Ridgewood, N.J.) N.J.), 2002-02, Vol.59 (2), p.227-231
Hauptverfasser:	Pansadoro, Vito, Emiliozzi, Paolo, de Paula, Francesco, Scarpone, Paolo, Pansadoro, Alberto, Sternberg, Cora N
Format:	Artikel
Sprache:	eng
Schlagworte:	Adjuvants, Immunologic - therapeutic use Adult Aged Aged, 80 and over Antineoplastic agents BCG Vaccine - therapeutic use Biological and medical sciences Carcinoma in Situ - drug therapy Carcinoma in Situ - pathology Carcinoma, Transitional Cell - drug therapy Carcinoma, Transitional Cell - mortality Carcinoma, Transitional Cell - pathology Disease Progression Female Follow-Up Studies Humans Immunotherapy Male Medical sciences Middle Aged Neoplasm Recurrence, Local - epidemiology Neoplasm Recurrence, Local - mortality Pharmacology. Drug treatments Urinary Bladder Neoplasms - drug therapy Urinary Bladder Neoplasms - mortality Urinary Bladder Neoplasms - pathology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!